Literature DB >> 6431009

Establishment of human monoclonal anti-DNA antibody producing cell lines.

T Sasaki, F Endo, M Mikami, Y Sekiguchi, K Tada, Y Ono, N Ishida, K Yoshinaga.   

Abstract

We developed a useful method for the establishment of stable cell lines producing human monoclonal anti-DNA antibody by in vitro Epstein-Barr virus infection. The practical limitation for the cloning was overcome by 2 procedures. One was a microculture system using a small number of the culture. Another was enrichment of anti-DNA producing cells at an early stage and prior to the cloning. The combination of these procedures allowed ready derivation of the cell lines secreting monoclonal anti-DNA antibody. Sixteen cell lines were cloned by utilizing colony formation methods in soft agarose. About 14-32 micrograms per ml of IgM with specific antibody activity were obtained in the supernatant of the cells. The antibody reacted with double-stranded and/or single-stranded DNA. These cells have been continuously producing the specific antibody for more than 3 years. We may extend this procedure for obtaining other autoantibodies, such as anti-T cell antibodies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6431009     DOI: 10.1016/0022-1759(84)90443-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  9 in total

1.  Variable regions of a human anti-DNA antibody O-81 possessing lupus nephritis-associated idiotype.

Authors:  Y Hirabayashi; Y Munakata; T Sasaki; H Sano
Journal:  Nucleic Acids Res       Date:  1992-05-25       Impact factor: 16.971

2.  Epstein-Barr virus-transformed B cells bearing idiotypes of anti-DNA autoantibodies.

Authors:  O Takai; T Sasaki; T Muryoi; E Tamate; K Yoshinaga; H Sano
Journal:  J Clin Immunol       Date:  1988-05       Impact factor: 8.317

3.  Incidence of anti-DNA idiotype-positive cells in human peripheral blood.

Authors:  O Takai; T Sasaki; T Muryoi; N Harata; H Hashimoto; K Yoshinaga
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

4.  Therapeutic treatment of New Zealand mouse disease by a limited number of anti-idiotypic antibodies conjugated with neocarzinostatin.

Authors:  N Harata; T Sasaki; H Osaki; T Saito; S Shibata; T Muryoi; O Takai; K Yoshinaga
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

5.  Binding specificity of antiidiotypic autoantibodies to anti-DNA antibodies in humans.

Authors:  T Sasaki; T Muryoi; O Takai; E Tamate; H Saito; K Yoshinaga
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

6.  Monoclonal human anti-DNA antibodies from EB virus-transformed lymphocytes of systemic lupus erythematosus (SLE) patients.

Authors:  T Sasaki; T Muryoi; Y Sekiguchi; E Tamate; K Yoshinaga; Y Kitagawa
Journal:  J Clin Immunol       Date:  1985-07       Impact factor: 8.317

7.  Selective elimination of anti-DNA antibody-producing cells by antiidiotypic antibody conjugated with neocarzinostatin.

Authors:  T Sasaki; T Muryoi; O Takai; E Tamate; Y Ono; Y Koide; N Ishida; K Yoshinaga
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

8.  Thymine and guanine base specificity of human myeloma proteins with anti-DNA activity.

Authors:  M Zouali; B D Stollar
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

9.  Heterogeneity of anti-idiotypic antibodies to anti-DNA antibodies in humans.

Authors:  T Muryoi; T Sasaki; N Harata; O Takai; E Tamate; K Yoshinaga
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.